Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

Job A. J. Verdonschot1†, João Pedro Ferreira2†, Pierpaolo Pellicori3, Hans-Peter Brunner-La Rocca4, Andrew L. Clark5, Franco Cosmi6, Joe Cuthbert5, Nicolas Girerd2, Beatrice Mariottoni6, Johannes Petutschnigg7, Patrick Rossignol2, John G. F. Cleland3, Faiez Zannad2† and Stephane R. B. Heymans4*† on behalf of HOMAGE “Heart Omics in AGEing” consortium

Abstract

Background: Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The “Heart OMics in AGEing” (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardiac remodeling in an at risk population, potentially slowing the progression towards HF. We compared the proteomic profile of patients with and without diabetes among patients at risk for HF in the HOMAGE trial.

Methods: Protein biomarkers (n = 276) from the Olink® Proseek-Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline and 9 months (or last visit) from HOMAGE trial participants including 217 patients with, and 310 without, diabetes.

Results: Twenty-one biomarkers were increased and five decreased in patients with diabetes compared to non-diabetics at baseline. The markers clustered mainly within inflammatory and proteolytic pathways, with granulin as the key-hub, as revealed by knowledge-induced network and subsequent gene enrichment analysis. Treatment with spironolactone in diabetic patients did not lead to large changes in biomarkers. The effects of spironolactone on NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function were similar in patients with and without diabetes (all interaction analyses p > 0.05).

Conclusions: Amongst patients at risk for HF, those with diabetes have higher plasma concentrations of proteins involved in inflammation and proteolysis. Diabetes does not influence the effects of spironolactone on the proteomic profile, and spironolactone produced anti-fibrotic, anti-remodelling, blood pressure and natriuretic peptide lowering effects regardless of diabetes status.

Trial registration NCT02556450.

Keywords: Diabetes, Biomarker, Heart failure, Spironolactone, Fibrosis

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
The HOMAGE (Heart OMics in AGEing) trial showed that treatment with spironolactone (vs. usual care) in patients at risk of developing HF led to a decrease in collagen synthesis markers, N-terminal pro brain natriuretic peptide (NT-proBNP), reduced blood pressure and improved cardiac remodelling [5, 6]. Small studies have suggested that spironolactone could impair endothelial function and increase glycated hemoglobin (HbA1c) in patients with DM [7, 8]. As spironolactone is a steroidal mineralocorticoid receptor antagonist (MRA) that is not specific for the mineralocorticoid receptor, it may exert other effects (e.g., cortisol elevation) on glucose and insulin metabolism. In a previous analysis we showed the influence of spironolactone on the proteome in the total HOMAGE trial population [9]. It remains unknown to what extent DM influences the effects of spironolactone on clinical and proteomic variables.

In this pre-specified secondary analysis of the HOMAGE trial, we aimed to (1) compare the clinical characteristics of patients with and without DM; (2) study the biomarker profiles, networks and pathways associated with DM at baseline, as compared to patients without diabetes; (3) to assess the effect of spironolactone on the circulating proteomic biomarkers in patients with DM; and (4) to explore whether the DM status might have modified the effect of spironolactone on the main outcomes assessed in the HOMAGE trial (level of collagen synthesis markers, NT-proBNP, echocardiographic measures of cardiac structure and function, and signs/symptoms).

Statistical analyses
We compared the characteristics of the patients with and without diabetes using the appropriate tests for continuous and categorical variables. To assess whether the biomarkers were expressed differently in patients with and without diabetes, we performed logistic regression analyses with diabetes as outcome variable and adjusting for age, sex, coronary artery disease, hypertension, body mass index and estimated glomerular filtration rate. Since proteins were measured using NPX values on a log2 scale, the odds ratio for each protein estimates the increase in the odds of diabetic status associated with a doubling in the protein concentration. We corrected the findings for multiple testing using a false discovery rate of 5%. After selecting the proteins with differential expression by diabetes status, we tested whether spironolactone could change the levels of the proteins. For consistency with the primary report, we used analysis of covariance (ANCOVA) comparing the difference in any changes between the control and spironolactone groups in the regression model [6].

A linear regression model was fitted, with the protein change (from baseline to last visit) as outcome variable, a binary variable to indicate the treatment group (control/spironolactone), and the baseline protein value (NPX) as covariates. The treatment effect was the coefficient that resulted from the comparison of spironolactone vs.
control in the regression model. Residual analysis was used to examine the fit of the model. No data transformation was required to meet the assumptions of linear regression. Similar analyses were performed for the protein change at 1 month. To study if the diabetes status could influence the response to spironolactone on the main outcomes of the study, we performed an ANCOVA analysis with a treatment-by-diabetes interaction term. Statistical analyses were performed using Stata® (version 16, StataCorp LP).

Bioinformatical and network analyses
We used knowledge-based network analysis with induced network approach by consensuspathDB (CPDB) online server (accessed on 24 November 2020) from Max Planck Institute for Molecular Genetics to identify the links among all significantly different protein biomarkers, based on knowledge of interactions (protein interactions, genetic interactions and biochemical interactions) [7]. The network analysis also identifies additional proteins limited to the first-degree interactors (intermediate nodes) linking our input proteins (seed nodes), with exclusion of low-confidence interactions and quantified by a z-score \( \leq 20 \) calculated for each intermediate node. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was used to analyse functional enrichment (GO biological processes and KEGG pathways) using proteins that were significantly increased or decreased in diabetic patients compared to non-diabetics at baseline.

Results
Clinical characteristics of the study population
Among the 527 patients included in the HOMAGE trial, 217 (41%) had diabetes. Compared to those without diabetes, patients with diabetes had a higher BMI, a higher blood pressure and heart rate (Table 1), were more likely to have a history of hypertension (93% vs. 68%; \( p < 0.001 \)), but less likely to have a history of coronary artery disease (47% vs. 90%; \( p < 0.001 \)). Among patients with diabetes, 176 (81%) were on metformin, and 38 (18%) were insulin-dependent. Left ventricular mass was greater (99 [84–114] vs. 91 [79–110] g/m²; \( p = 0.005 \)) and E/e′ ratio higher (10.1 [8–12] vs. 8.9 [7–11]; \( p < 0.001 \)) in patients with diabetes; however, left atrial volume and NT-proBNP were similar.

Proteomic profile at baseline
Compared to patients without diabetes, those with diabetes had greater expression of 21 proteins and lower expression of 5 proteins after adjustment for age, sex, hypertension, body mass index, coronary artery disease, estimated glomerular filtration rate and multiple test correction at a FDRq < 0.05 level (Table 2).

The results of the network analysis are shown in Fig. 1. The central core of the network is characterized by (lysosomal) protease activity reflected in matrix metalloproteinase 7 (MMP7), cathepsin D (CTSD), cathepsin Z (CTSZ) and prostasin (PRSS8). A large number of edges and nodes connect through granulin (GRN), placing this protein as an important hub connecting the proteases with the chemokines [cluster of chemokine (CC-motif) ligand (CCL) 11 and 15 and chemokine (CXC motif) ligand (CXCL) 10]. Pathway enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) terms placed 13 proteins in a biological pathway involving inflammation or lysosomal proteolytic activity (Table 3). An additional analysis using the Gene Ontology terms, showed that the top 10 enriched pathways were all implicated in inflammation (Fig. 2; Additional file 1: Table S2).

Proteomic changes after spironolactone in diabetes patients
Three proteins fell significantly (COL1A1, PICP and SELE) and one protein increased (MMP7) after 9 months of spironolactone treatment (Additional file 1: Table S3). Overall, there was no prominent effect of spironolactone on the proteomic markers in diabetic patients. The activity of the biological processes at baseline in diabetic patients (Table 3; Fig. 2) was unaltered after 9 months of spironolactone treatment.

Interaction of diabetes status with the main trial outcomes
The primary and secondary outcomes measures in the HOMAGE trial were: PICP and PIIINP (markers of collagen synthesis), NT-proBNP, systolic and diastolic blood pressure, echocardiographic left atrial volume and left ventricular mass. The presence of diabetes did not modify the effect of spironolactone on any of those outcomes (Additional file 1: Table S4), indicating that there was no superior or inferior effect of spironolactone on serum markers of collagen metabolism, cardiac structure and function in patients with DM.

Discussion
This study investigated the proteomic profile of patients at risk for heart failure treated with spironolactone, with a special focus on DM (Fig. 3). The main findings of the study are: (i) patients with diabetes have a distinct proteome profile, whereby twenty-one biomarkers are higher, while five were lower compared to those without diabetes; (ii) cluster analysis revealed that the distinct proteomic profile is indicative of increased activation of inflammatory and proteolytic pathways in patients with DM.
Table 1  Baseline characteristics according to diabetic status

| Variable                                    | Level       | Patients without diabetes (n = 310)       | Patients with diabetes (n = 217)       | p-value |
|---------------------------------------------|-------------|-------------------------------------------|---------------------------------------|---------|
| Age (years)                                 | 71.9 [68.5–78.1] | 73.5 [69.0–79.0]                           | 0.064                                 |
| Male gender                                 | 235 (75.8%)  | 157 (72.4%)                               | 0.37                                  |
| Smoking status                              | Never       | 102 (32.9%)                               | 76 (35.0%)                           | 0.90    |
|                                              | Ex          | 177 (57.1%)                               | 123 (56.7%)                          |         |
|                                              | Current     | 28 (9.0%)                                 | 16 (7.4%)                            |         |
| Body mass index (kg/m²)                     | 27.3 [25.0–29.9] | 29.7 [26.5–33.9]                           | <0.001                                |
| Systolic blood pressure (mmHg)              | 139.0 [124.0–154.0] | 141.0 [132.0–157.0]                      | 0.013                                 |
| Diastolic blood pressure (mmHg)             | 79.0 [72.0–86.0]  | 77.0 [71.0–84.0]                           | 0.097                                 |
| Heart rate (pm)                             | 59.0 [54.0–65.0]  | 64.0 [57.0–70.0]                           | <0.001                                |
| Number of shuttles completed (shuttle-walk test) | 54 [35–71] | 44 [26–61]                                | <0.001                                |
| Comorbidities                                |             |                                           |                                       |         |
| Coronary artery disease                     | 278 (89.7%)  | 101 (46.5%)                               | <0.001                                |
| Myocardial infarction                       | 163 (52.6%)  | 51 (50.0%)                                | 0.13                                  |
| PCI                                         | 196 (70.5%)  | 69 (67.6%)                                | 0.59                                  |
| CABG                                        | 97 (34.9%)   | 39 (38.2%)                                | 0.55                                  |
| Hypertension                                | 211 (68.1%)  | 202 (93.1%)                               | <0.001                                |
| Stroke/TIA                                  | 14 (4.5%)    | 14 (6.5%)                                 | 0.33                                  |
| COPD                                        | 22 (7.1%)    | 11 (5.1%)                                 | 0.34                                  |
| Medication                                  |             |                                           |                                       |         |
| Antiplatelet therapy                        | 267 (86.1%)  | 147 (67.7%)                               | <0.001                                |
| Beta blocker                                | 239 (77.1%)  | 127 (58.5%)                               | <0.001                                |
| ACE-inhibitor                               | 157 (50.6%)  | 118 (54.4%)                               | 0.40                                  |
| Angiotensin receptor blocker                | 77 (24.8%)   | 68 (31.3%)                                | 0.10                                  |
| Calcium channel blocker                     | 56 (18.1%)   | 54 (24.9%)                                | 0.058                                 |
| Thiazides                                   | 33 (10.6%)   | 54 (24.9%)                                | <0.001                                |
| Statin/lipid lowering drug                  | 269 (86.8%)  | 166 (76.5%)                               | 0.002                                 |
| Insulin                                     | 0 (0.0%)     | 38 (17.5%)                                | <0.001                                |
| Metformin                                   | 0 (0.0%)     | 176 (81.1%)                               | <0.001                                |
| Sulfinylureas                                | 0 (0.0%)     | 41 (18.9%)                                | <0.001                                |
| DPP4-inhibitor                              | 0 (0.0%)     | 33 (15.2%)                                | <0.001                                |
| Echocardiography                            |             |                                           |                                       |         |
| Left ventricular ejection fraction (%)      | 62.8 [56.5–66.0] | 63.1 [59.2–66.9]                           | 0.35                                  |
| Left ventricular mass (g/m²)                | 91.0 [78.5–109.9] | 99.0 [84.2–114.1]                      | 0.005                                 |
| Left ventricular hypertrophy                | 106 (34.2%)  | 87 (40.1%)                                | 0.17                                  |
| Left atrial volume (g/m²)                   | 30.8 [26.0–36.5] | 29.4 [25.1–35.6]                           | 0.32                                  |
| E/e' ratio                                  | 8.9 [6.9–11.1] | 10.1 [8.3–12.0]                           | <0.001                                |
| E/A ratio                                   | 0.8 [0.7–1.0]  | 0.8 [0.7–1.0]                             | 0.21                                  |
| TAPSE (mm)                                  | 21.4 [16.7–26.3] | 22.5 [17.5–26.8]                          | 0.28                                  |
| MAPSE (mm)                                  | 15.5 [13.6–17.7] | 15.0 [13.1–17.4]                          | 0.38                                  |
| Laboratory                                  |             |                                           |                                       |         |
| eGFR (ml/min/1.73 m²)                       | 72.0 [62.0–82.9] | 72.8 [59.0–86.5]                           | 0.75                                  |
| Urea (mmol/l)                               | 7.5 [5.6–13.2]  | 10.7 [6.4–15.7]                           | <0.001                                |
| Haemoglobin (g/dl)                          | 14.2 [13.3–15.0] | 13.8 [12.8–14.7]                          | 0.002                                 |
| Sodium (mmol/l)                             | 140.0 [138.0–141.0] | 139.0 [137.0–141.0]                     | 0.052                                 |
| Potassium (mmol/l)                          | 4.3 [4.1–4.6]   | 4.3 [4.0–4.5]                             | 0.12                                  |
| NT-proBNP, ng/l                             | 205 [129–350]  | 229 [146–373]                             | 0.25                                  |
| Galectin-3, ng/ml                           | 15.4 [13.1–18.9] | 17.4 [14.4–20.9]                          | <0.001                                |
| High-sensitivity Troponin T, pg/ml           | 11.6 [8.2–16.0]  | 14.1 [10.3–21.1]                          | <0.001                                |
...diabetes; and (iii) diabetic status did not influence the treatment response to spironolactone with respect to change in the proteomic profile, as well as to the anti-fibrotic, anti-remodelling, blood pressure and natriuretic peptide lowering effects. It is unlikely that diabetic status modified the effect of spironolactone observed in the HOMAGE trial.

**Proteomic profile of patients with diabetes**

Patients with DM had an up-regulation of inflammatory and proteolytic pathways, suggesting that inflammation and proteolysis mechanisms (i.e. an increased protein turn-over via the lysosomal proteolytic system) are active and distinctive for patients with DM compared to non-diabetic patients at risk of developing HF. Based on our data we can not state any causal relationship between these proteins and pathways and diabetes. However, it seems that the observations are independent of coronary artery disease, hypertension, BMI, age, sex and kidney function. Our findings are in line with a previous network and pathway analysis in patients with both diabetes and HF, showing a similar association between DM and inflammation, protein phosphorylation, and neutrophil degranulation mechanistic

| Positive association (n = 21) |
|-------------------------------|
| Interleukin-1 receptor type 1  | il1rt1   | 4.52 (2.41–8.5) | 0.00001  | 0.0005 |
| Cathepsin d                   | ctsd     | 3.49 (2.13–5.72) | 0.00001  | 0.0005 |
| Growth differentiation factor 15 | gdf15    | 3.41 (2.39–4.87) | 0.00001  | 0.0005 |
| Galectin-4                    | gal4     | 2.95 (1.95–4.45) | 0.00001  | 0.0005 |
| E-selectin                    | sele     | 2.38 (1.64–3.45) | 0.00001  | 0.0005 |
| Eotaxin                       | ccl11    | 2.96 (1.79–4.9) | 0.00002  | 0.0009 |
| Leukemia inhibitory factor receptor | lifr  | 4.4 (2.15–9.04) | 0.0005  | 0.0017 |
| Kidney injury molecule         | kim1     | 1.79 (1.35–2.38) | 0.0005  | 0.0017 |
| Cathepsin z                   | ctsz     | 3.1 (1.78–5.41) | 0.00007  | 0.0019 |
| Hydroxycid oxidase 1          | haoxl    | 1.44 (1.2–1.72) | 0.00007  | 0.0019 |
| P-selectin glycoprotein ligand 1 | psogl1 | 4.23 (1.95–9.16) | 0.00026  | 0.0054 |
| Interleukin-18 receptor 1      | il18r1   | 2.35 (1.43–3.87) | 0.00074  | 0.014 |
| Prostasin                     | prss8    | 2.97 (1.55–5.69) | 0.00102  | 0.0173 |
| C–C motif chemokine 15        | ccl15    | 2.13 (1.34–3.38) | 0.00135  | 0.0215 |
| Interleukin-10                | il10     | 1.74 (1.23–2.45) | 0.00168  | 0.024 |
| Gastric intrinsic factor       | gif      | 1.34 (1.11–1.6) | 0.00196  | 0.0253 |
| Matrix metalloprotease 7       | mmp7     | 1.92 (1.27–2.9) | 0.00187  | 0.0253 |
| Granulin                      | grn      | 2.66 (1.42–5) | 0.00237  | 0.0292 |
| Granulolinase                  | fs       | 2.16 (1.29–3.61) | 0.00333  | 0.0392 |
| Alpha-L-iduronidase            | idua     | 2.04 (1.26–3.29) | 0.0036  | 0.0407 |
| Osteoprotegerin                | opg      | 2.43 (1.32–4.45) | 0.00422  | 0.044 |

| Negative association (n = 5) |
|-------------------------------|
| Collagen type 1 alpha 1       | col1a1   | 0.33 (0.19–0.58) | 0.00013  | 0.003 |
| Procollagen type 1 carboxy-terminal propeptide | picp | 0.36 (0.22–0.62) | 0.00016  | 0.0036 |
| Lipoprotein lipase            | lpl      | 0.48 (0.31–0.74) | 0.00085  | 0.0154 |
| Matrix extracellular phosphoglycoprotein | mepe | 0.43 (0.26–0.73) | 0.00167  | 0.024 |
| C–C motif chemokine 10        | ccl10    | 0.65 (0.48–0.87) | 0.00418  | 0.044 |
pathways [4]. The top 5 proteins we identified (GDF15, GAL4, IL1RT1, CTSD and SELE) are robustly associated with diabetes in a variety of studies, consistent with our findings [2–4].

Growth differentiation factor 15 (GDF15) is a protein which is upregulated as consequence of organ injury, as seen in heart and kidney disease [10]. In patients with HF, GDF15 is a strong prognostic marker [11]. However, in diabetic patients without HF, GDF15 may be associated with the effect of metformin. Metformin partly works through stimulation of GDF15 expression, which is associated with weight loss and improved insulin sensitivity in patients with DM [12, 13]. On the other hand, GDF15 levels are increased in patients with HF, and GDF15 is associated with diastolic dysfunction, as defined by an elevated E/e’ [14, 15], which was also observed in the patients with DM in our study.

Galectin-4 (GAL4) is a small lectin protein and is involved in protein trafficking from the inside of the cell towards the cell membrane. This protein was detected in all previous proteomics screenings in diabetic patients, confirming a strong association between DM and GAL4. One of the proteins which is trafficked by GAL4 is the protease dipeptidyl peptidase-4 (DPP4). DPP4 subsequently deactivates proglucagon-derived peptide glucagon-like peptide-1 (GLP1). Inhibitors of DPP4 and GLP1-analologues are both used for lowering glucose in patients with DM but do not improve HF outcomes. An increase in GAL4 leads to increased activity of DPP4, which reduces the activity of GLP1, contributing to
insulin resistance and DM development [3]. Although the association between GAL4 and DM is established, the exact mechanistic and causal role remains unknown.

**Interleukin-1 receptor type 1 (IL1R1)** is the receptor for IL1A, IL1B and IL1RA and is responsible for the IL1-dependent activation of the NFκB pathway. However, recently IL1R1 has been identified as one of the key mediators in leptin sensitivity and IL1R1 deficiency leads to a higher degree of obesity and metabolic disturbance [16]. Pro-inflammatory signalling can have beneficial metabolic effects: for example, inflammatory signalling is essential for proper adipose tissue remodelling and expansion which prevents ectopic lipid accumulation and subsequent glucose intolerance [17, 18]. Cytokine resistance as a consequence of chronic systemic inflammation could be one of the mechanisms underlying the development of DM type 2. It may be that the higher levels of inflammatory proteins we observed could be partially explained by cytokine resistance in diabetic patients.

**Cathepsin D (CTSD)** is a lysosomal endopeptidase which is involved in intracellular protein turnover and extracellular matrix breakdown. Levels of CTSD have been associated with DM in patients with and without HF [2, 3, 19], and are positively associated with insulin resistance [20]. The family of cathepsins were well-represented in the network analysis, showing a link between inflammation and proteolysis. It has been suggested that CTSD acts as a mediator between obesity and systemic inflammation, which could contribute to the cytokine resistance mentioned above [21].

**E-selectin (SELE)** is a selectin cell adhesion molecule expressed only on endothelial cells activated by cytokines. Levels of SELE and other cellular adhesion molecules have previously been associated with DM, increasing HbA1c levels, blood pressure and microalbuminuria, all reflecting (early) endothelial dysfunction [22–24].

**Granulin as important node in the diabetes pathophysiology**

Granulin was identified as a key hub in the network based on the proteomic profile of patients with DM. Granulin is cleaved from the precursor progranulin and their exact function remains unknown, but both forms have been implicated in inflammation and protein homeostasis via the lysosomal pathway (e.g. CTSD). Mechanistically (pro)granulin seems to play an important role in the proteomic network of diabetic patients and is related to insulin resistance, obesity, inflammation and proteolysis [25]. Mice deficient in *Grn* have lower body weight, fat mass and adipocyte size than wild-type mice receiving a standard diet. The loss of granulin protected the mice against obesity and insulin resistance induced by a high fat diet [25]. Granulin increases IL6-mediated expression...
of cytokine signalling 3 (SOCS3), which inhibits phosphorylation of insulin receptor substrate-1 (IRS1) [25].

A previous study has also inferred that granulin is a key hub in the proteomic profile of patients with HF and DM based on other biomarkers (although granulin itself was not actually measured) [4]. We now identify granulin as a biomarker which is elevated in diabetic patients.

**Spironolactone treatment in patients with diabetes**

The study end of the HOMAGE trial was determined at 9 months, as it is expected that the biochemical response of spironolactone can be observed after 9 months of treatment. At the last visit of a patient, additional blood sampling was performed for proteomic analysis. Spironolactone did not significantly change the proteomic profiles of patients with diabetes, but yielded the same clinical benefits as in the complete HOMAGE cohort. The four proteins which were significantly modified in diabetic patients after 9 months of spironolactone treatment (COL1A1, PICP, SELE and MMP7) are altered in the same direction as in the complete population, indicating that the effects are not specific for diabetic patients [9]. These proteins are implicated in extracellular matrix metabolism (COL1A1, PICP), cell-cell adhesion (SELE) and proteolysis (MMP7). Furthermore, diabetes did not modify the effect of spironolactone on serum markers of collagen metabolism, indicating that patients with diabetes benefited equally from the antifibrotic effect of spironolactone compared to non-diabetics. No metabolic pathways detrimental for diabetic patients was worsened with spironolactone.

**Limitations**

We tested the effect of spironolactone on multiple proteins applying a correction for test multiplicity to limit the occurrence of false positive findings; however, as HOMAGE was a randomized controlled trial, other proteins, whose levels were also significantly changed with spironolactone, might also be implicated in relevant pathways and biological processes and might be worth exploring in further studies. Additionally, many of the highlighted mechanisms should be furtherly replicated and confirmed at a cellular level. Our results and previous findings highlight granulin as an important hub in the pathophysiology of diabetes which should receive priority for further study. Due to the
Conclusions
Diabetic patients at risk of developing HF have a proteomic bioprofile which differs from controls without diabetes, pointing towards mechanisms related to inflammation and protein homeostasis. Treatment with spironolactone did not influence the overall proteomic profile of diabetic compared to non-diabetic patients. Patients benefited similarly from spironolactone with respect to its anti-fibrotic, anti-remodeling, blood pressure and natriuretic peptide lowering effects regardless of the diabetes status.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-021-01357-9.

Additional file 1: Table S1. Protein names and respective Olink® panel sorted in alphabetical order. Table S2. Pathway enrichment analysis using GO terms. Table S3. Proteins which are significantly altered in diabetic patients after 9 months of spironolactone treatment. Table S4. Interaction analysis between diabetic status of the patients and spironolactone treatment for the primary and secondary outcomes of the HOMAGE trial.

Acknowledgements
Not applicable.

Authors' contributions
Jv and JPF designed the study, analysed the data and drafted the manuscript. PP, JC, BM and JPF collected the data and substantially revised the manuscript. HPBLR, AC, FC, NG, PR, JC, FZ and SH gathered the funding, supervised the study at their respective location, interpreted the data and substantially revised the manuscript. All authors read and approved the final manuscript.

Funding
The research leading to these results has received funding from the European Union Commission’s Seventh Framework programme under Grant Agreement No. 305507 (HOMAGE). S.H: This manuscript has been possible thanks to the Union Commission’s Seventh Framework programme under Grant Agreement. The research leading to these results has received funding from the European Commission’s Seventh Framework programme under Grant Agreement.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by all relevant ethics committees and regulatory bodies. All participants provided written informed consent prior to study-specific procedures.

Consent for publication
There is no data of individual persons included in the manuscript.

Competing interests
The authors have no relevant conflicts of interest to disclose with regards to the content of this manuscript.

Author details
1 Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands. 2 Centre d’Investigations Cliniques Pluriéthnique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale 1116, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative – Cardiovascular and Renal Clinical Trials, Nancy, France. 3 Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow G12 8QQ, UK. 4 Department of Cardiology, Maastricht University Medical Center (MUMC+), PO Box 5800, 6202 AZ Maastricht, The Netherlands. 5 Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, East Riding of Yorkshire, UK. 6 Department of Cardiology, Cortona Hospital, Arezzo, Italy. 7 Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin Institute of Health (BIH), and German Centre for Cardiovascular research (DZHK), Partner Site Berlin, Berlin, Germany.

Received: 3 June 2021 Accepted: 29 July 2021

Published online: 09 August 2021

References
1. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Hoffner S, Katz R, Lindenfeld J, Lovews BD, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42(5):914–22.
2. Beijer K, Nowak C, Sundström J, Amlöv J, Fahl T, Lind L. In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study. Diabetologia. 2019;62(11):1998–2006.
3. Molvin J, Pareek M, Jujic A, Melander O, Råstam L, Lindblad U, Daka B, Leösdöttir M, Nilsson PM, Olsen MH, et al. Using a targeted proteomics chip to explore pathophysiological pathways for incident diabetes—the Malmö preventive project. Sci Rep. 2019;9(1):1272.
4. Tromp J, Voors AA, Sharma A, Ferreira JP, Ouwerkerk W, Hillege HL, Gomez KA, Dickstein K, Anker SD, Mietra M, et al. Distinct pathological pathways in patients with heart failure and diabetes. JACC Heart Fail. 2020;8(3):234–42.
5. Pellisier P, Ferreira JP, Mariotti J, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, et al. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail. 2020;22(9):1711–23.
6. Clevel JD, Ferreira JP, Mariotti B, Pellisier P, Cuthbert JJ, Verdonschot J, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the Heart OMics in AGing (HOMAGE) randomized clinical trial. Eur J Heart Fail. 2020;22(6):684–96.
7. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004;47(10):1678–94.
8. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Hone M. Effect of eplerenone versus spironolactone on cortisol and
9. Ferreira JP, Verdonschot J, Wang P, Pizard A, Coller T, Ahmed FZ, Brunner-La-Rocca H-P, Clark AL, Cosmi F, Cuthbert J, et al. Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail. 2021;9(4):268–77.

10. Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006;98(3):294–7.

11. Sharma A, Stevens SR, Lucas J, Fiuza M, Adams KF, Whellan DJ, Donahue MP, Kitzman DW, Prigila JL, Zannad F, et al. Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC Heart Fail. 2017;5(10):724–34.

12. Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, Lu R, Raphenya AR, Kabiri M, McArthur AG, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019;1(12):1202–8.

13. Coll AP, Chen M, Taskar P, Rimington D, Patel S, Tadross JA, Cimino I, Yang M, Welsh P, Virtue S, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444–8.

14. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2014;114(6):893–4.

15. Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Honka PS, Metra M, Anker SD, Cleland JG, Dickstein K, et al. Identifying pathophysiological mechanisms in heart failure with preserved versus preserved ejection fraction. J Am Coll Cardiol. 2018;72(10):1081–90.

16. Feng X, Guan D, Auen T, Choi JW, Salazar Hernandez MA, Lee J, Chun H, Faruk F, Kaplun E, Herbert Z, et al. IL1R1 is required for calpastatin leptin-sensitization and ameliorates obesity effects. Nat Med. 2019;25(4):575–82.

17. Liu J, Ibi D, Taniguchi K, Lee J, Herrema H, Akosman B, Mucka R, Salazar Hernandez MA, Uyar MF, Park SW, et al. Inflammation improves glucose homeostasis through IKKβ-XBP1s interaction. Cell. 2016;167(4):1052–1066. e1018.

18. Wernstedt Aserholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, Scherer PE. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014;20(1):103–18.

19. Hoes MF, Tromp J, Ouwerkerk W, Bomer N, Oberdorf-Maass SJ, Samani NJ, Ng LL, Lang CC, van der Harst P, Hillege H, et al. The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. Eur J Heart Fail. 2019;22(1):2102–11.

20. Ding L, Goossens GH, Oligschläger Y, Houben T, Blaak EE, Shiri-Sverdlov R. Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans. Diabetologia. 2020;63(2):374–84.

21. Eguchi A, Feldstein AE. Lysosomal cathepsin D contributes to cell death during adipocyte hypertrophy. Adipocyte. 2013;2(3):170–5.

22. Tryggestad JB, Shah RD, Braffett BH, Bacha F, Gidding SS, Gubitosi-Klug RA, Shah AS, Urbina EM, Levitt Katz LE. Circulating adiponectin molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the treatment options for type 2 diabetes in adolescent and youth study. Pediatr Diabetes. 2020;21(6):923–31.

23. Zemlin AE, Matsha TE, Kengne AP, Hon GM, Erasmus RT. Correlation of E-selectin concentrations with carotid intima-media thickness and cardio-metabolic profile of mixed ancestry South Africans: a cross-sectional study. Ann Clin Biochem. 2017;54(1):92–100.

24. Sass C, Pallaud C, Zannad F, Visvikis S. Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. Hum Genet. 2000;107(1):58–61.

25. Matsuoka T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, Tamori Y, Yokoi N, Watanabe M, Matsuo E, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 2012;15(1):38–50.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.